General MedicationsINTRATRACHEALStandard
SURVANTA
BERACTANT
Standard Dose
25MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview SURVANTA is listed in Drugs@FDA under application 020032 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient BERACTANT Form and strength SUSPENSION;INTRATRACHEAL - 25MG/ML Sponsor ABBVIE Submission history Latest submission status date: 2022-07-15 00:00:00.
Structured Monograph
Clinical summary
Approval overview SURVANTA is listed in Drugs@FDA under application 020032 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient BERACTANT Form and strength SUSPENSION;INTRATRACHEAL - 25MG/ML Sponsor ABBVIE Submission history Latest submission status date: 2022-07-15 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.